Sign in PRO MARKETPLACE SUBSCRIBE

Premium
My Portfolio
My Authors
- My Authors
- Author Email Alerts
Top Stocks
- Ratings Screener
- ETF Screener
Latest News
Markets
Stock Ideas
Dividends
ETFs
Investing Strategy
Watch & Listen
- Podcasts
- Videos

Knowledge Base
Feedback Forum

OncoCyte (OCX) Investor Presentation - Slideshow

Dec. 2, 2020 11:50 AM ET

|

| About: OncoCyte Corporation (OCX)

by: SA Transcripts

The following slide deck was published by OncoCyte Corporation in conjunction with this event.

140

Investor Presentation

Forward Looking Statement

Mission Statement

Oncocyte Growth Engines

Well Positioned To Deliver Solid Enterprise Value

Oncocyte’s Determa Platform Strategy

Solid Pipeline Targeting a Large Served Available Market

DetermaRx

Early-Stage Lung Cancer can be Deadly

Recurrence After Surgery

The Predictive Biomarker Paradox in NSCLC

Prospective Study Design

North American IASLC Update – 250 Patients

Improves Survival

Outperforms NCCN Criteria

…Emerging Standard of Care

Clinical Papers

EGFR Mutations and DetermaRx

Available at 70+ Health Systems

2021 Salesforce Scaling to Drive Mass Adoption

Impacting Patient Care and

DetermaIO

Addresses Important Unmet Need

FIRST Test to Measure the ENTIRE Tumor

Understanding

NSCLC Checkpoint Inhibitor Clinical Performance Data

Identifies More Patients for

TNBC Data From MD Anderson

Proprietary Assay for Broad Clinical Use

Road to Commercialization

Biopharma Services

Comprehensive Biopharma Services Offering

Utility of Our Proprietary Tests for

Oncocyte has Tremendous Organizational Velocity

Oncocyte Growth Drivers

IR 0507 0920

New Data on EGFR TKI in Adjuvant Setting

Experienced Leadership Team

DetermaIO Derived from a Well-Published

Click to enlarge

Notes:

Follow SA Transcripts and get email alerts

Disagree with this article? Submit your own.

To report a factual error in this article, click here.

Your feedback matters to us!

|

Advertise with Us

|

|

|

|

|

|

|

Market Data Sources

|

© 2020 Seeking Alpha